Tehila Ben Moshe, Ph.D.
Co-Founder, Chairperson & Chief Executive Officer
Tehila is the Co-Founder of Biond. She has served as Biond’s CEO and Board of Directors chairperson since the company’s inception. Tehila brings over a decade of scientific excellence and entrepreneurial leadership in biotech and pharma, combined with proven leadership skills and business acumen. Prior to founding Biond, Tehila was the CEO of cCAM Biotherapeutics and led the immuno-oncology company from launch through drug discovery and development and early stage clinical trials. The company was subsequently acquired by Merck (MSD) in 2015. cCAM was one of the first Israeli biotech companies to be acquired by a top pharma based on pre-clinical data, generating 10X return to investors in less than 3 years. Prior to her entrepreneurial career, Tehila led R&D projects at Protalix Biotherapeutics (NYSE/TASE: PLX) driving the development of ‘Bio-Better’ proteins from early stage up to clinic trials. Tehila holds a Ph.D. in Biochemistry from the Weizmann Institute where she studied immune signaling pathways in health and disease. She holds undergraduate degrees in Neuroimmunology and Biotechnology from Bar-Ilan University and the Hebrew University, respectively. She is the author of multiple patents and peer-reviewed scientific publications.
Ori Shilo, MBA
Co-Founder & Chief Financial Officer
Ori is the Co-Founder of Biond. He serves as the company’s CFO and a member of its Board of Directors since inception. Prior to launching Biond, Ori was Co-Founder, CFO & Deputy CEO and Director at RedHill Biopharma (NASDAQ: RDHL), a late stage drug development company. During his time at RedHill he led the company’s IPO in the Tel-Aviv Stock Exchange and its dual listing on NASDAQ including several private and public financing rounds totaling over $100 million as well as overseeing two phase 3 and three phase 2 trials. Prior to RedHill, Ori was partner in ProSeed Capital Holding CVA, a Belgium-based boutique investment firm, responsible for investments and banking activities in Israel. Ori has over 20 year of experience in investment banking and consultancy for the pharma/biotech field and as a Co-Founder of pharma/biotech companies.
Yair Sapir, Ph.D., MBA
Chief Operations Officer
Yair is a senior Biotech executive with extensive experience in drug development and has served as Biond’s COO since its inception. He has more than 15 years of experience in managing and conducting translational research with a wide knowhow in development of first-in-class antibodies for the treatment of cancer and autoimmune diseases. He was Director of Development and played a critical role in the success of cCAM Biotherapeutics where he oversaw the development of its lead agent. Yair holds a Ph.D. in immunology and an MBA from the Technion – Israel Institute of Technology.
Avidor Shulman, Ph.D.
Avidor has served as Biond’s CTO since its inception and has over 20 years of experience in applied R&D, including all aspects of product development, innovation management & entrepreneurship. Prior to Biond, Avidor was Senior Director of Protein Chemistry at Protalix Biotherapeutics (NASDAQ: PLX) where he established the Protein Chemistry department. Avidor and his team led the development of Protalix’ pipeline of ‘Bio-Better’ products by implementing chemistry tools on biologics. Avidor was instrumental in the development of pegunigalsidase alfa, a breakthrough chemically modified enzyme replacement therapy for Fabry Disease currently awaiting FDA approval, and played a pivotal part in all CMC and regulatory efforts leading to its BLA submission. Avidor served as Director of Innovation at Enzymotec before joining Protalix. He holds a Ph.D. in organic chemistry from the Technion – Israel Institute of Technology and has spent most of his professional career on the interface between chemistry and biology.
Ilana Mandel, Ph.D.
Ilana has served as Biond’s VP R&D since its inception and brings extensive knowledge and experience in immunology and innovative drug development. Prior to Biond, Ilana was Director of Research and Discovery at cCAM Biotherapeutics where she led the research of the company’s lead product from early stage up to clinical studies and managed several pipeline projects. Ilana holds a Ph.D. in immunology from the Technion – Israel Institute of Technology where her research focused on immunomodulatory mechanisms in autoimmunity.
Itay Friedman, M.D.
VP Clinical Development
Itay serves as Biond’s VP Clinical Development since 2018. He has over 15 years of diversified R&D and Commercial experience developing and delivering innovative medicines and medical technologies. Itay joined Biond from Bristol-Myer Squibb (BMS) where he was Medical Affairs lead for Oncology, Hemato-oncology, and Virology brands in addition to holding regional Business Development and global commercial roles. Prior to BMS he served as Director of Clinical Services and Product Owner at Perigen, a digital healthcare company developing innovative perinatal software solutions. Itay received a B.Sc. with honors, and earned his M.D. from the Faculty of Medicine, Hebrew University, Israel.
Sharon Hashmueli, Ph.D.
VP Regulatory Affairs & CMC
Sharon has served as Biond’s VP of Regulatory Affairs & CMC since its inception. She has over 15 years of experience in CMC and regulatory product development of biologics (pre-IND, IND, CTA, and NDA) including recombinant proteins and antibodies. Prior to Biond, Sharon was VP Regulatory and Clinical Affairs of cCAM Biotherapeutics (acquired by Merck) developing a novel immune checkpoint inhibitor for cancer. Beforehand at Protalix Biotherapeutics, she played a significant role in the development of Elelyso, an FDA approved treatment for Gauche disease marketed by Pfizer. Sharon holds a Ph.D. in Biotechnology and Food Engineering from the Technion – Israel Institute of Technology.